Summary

Eligibility
for people ages 2-45 (full criteria)
Healthy Volunteers
healthy people welcome
Location
at San Francisco, California and other locations
Dates
study started
completion around
Principal Investigator
by Stephen Gitelman, MD
Headshot of Stephen Gitelman
Stephen Gitelman

Description

Summary

Details

Keywords

Diabetes Mellitus, Type 1, "at risk" for developing type 1 diabetes, T1DM, T1D, juvenile diabetes, Type 1 Diabetes TrialNet, TrialNet, Type 1 Diabetes Mellitus, Annual Re-Testing/Annual Metabolic Monitoring, Semi-Annual Metabolic Monitoring

Eligibility

Locations

  • UCSF accepting new patients
    San Francisco California 94143-0434 United States
  • Stanford University Medical Center accepting new patients
    Stanford California 94305-5208 United States

Lead Scientist at UCSF

  • Stephen Gitelman, MD
    Dr. Gitelman is a physician scientist involved in studies to determine what causes type 1 diabetes mellitus (T1DM), and in clinical trials to prevent disease development, or preserve beta cell function in those recently diagnosed. To this end, he has been an active investigator in the NIH-sponsored TrialNet and Immune Tolerance Network consortia, and other immunotherapy trials in T1DM.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of South Florida
Links
TrialNet Study Group Type 1 Diabetes Clinical Trials American Diabetes Association
ID
NCT00097292
Study Type
Observational
Participants
Expecting 75000 study participants
Last Updated